Printer Friendly

Celgene receives Refusal to File letter from FDA regarding ozanimod NDA.

Celgene Corporation announced that it has received a Refusal to File letter from the United States Food and Drug Administration regarding its New Drug Application for ozanimod in development for the treatment of patients with relapsing forms of multiple sclerosis. Ozanimod is a novel, oral, selective sphingosine 1-phosphate 1 and 5 receptor modulator. Upon its preliminary review, the FDA determined that the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review. Celgene intends to seek immediate guidance, including requesting a Type A meeting with the FDA, to ascertain what additional information will be required to resubmit the NDA.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Feb 27, 2018
Previous Article:TiVo announces plan to explore alternatives to maximize shareholder value.
Next Article:Discovery, Scripps Networks announce election deadline for Scripps shareholders.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters